Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Syndax Pharmaceuticals Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.22
2.11
1.52
1.52
1.52
140
0
0
23.7
172
Research and development
31.7
48.2
60.1
43
50.4
88.2
118
163
242
259
Selling, general and administrative
25.2
33.3
66.9
121
180
General and administrative
13.3
15.9
17.3
16.1
22.5
25.2
33.3
Operating expenses
45
64.1
77.4
59.1
72.9
113
152
230
363
445
Operating income
-43.8
-62
-75.9
-57.5
-71.4
26.2
-152
-230
-340
-273
Interest expense
2.36
1.9
3.14
0.21
-0
0.01
Interest income
1.94
1.57
0.84
0.4
5.87
21.2
26.1
22.7
Other non-operating income
-0.71
1.15
1.92
1.49
-1.74
-1.29
2.42
20.6
20.9
-12.3
Income tax
0
0
0
0
0
0
0.43
Net income
-44.5
-60.8
-74
-56
-73.2
24.9
-149
-209
-319
-285
EBITDA
-43.7
-61.9
-75.8
-57.4
-71.3
69.2
-119
-218
-332
-267
EPS, basic
-3.22
-2.90
-2.92
-1.84
-1.87
0.48
-2.46
-2.98
-3.72
-3.29
EPS, diluted
-3.22
-2.90
-2.92
-1.84
-1.87
0.46
-2.46
-2.98
-3.72
-3.29
Shares, basic (weighted)
14.6
21
25.4
30.5
41.3
52.1
60.8
70.4
85.6
86.6
Shares, diluted (weighted)
14.6
21
25.4
30.5
41.3
53.6
60.8
70.4
85.6
86.6
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
23.8
35.2
33.8
24.6
115
222
74.4
295
154
135
Short-term investments
81.5
94.8
47.1
35.2
178
218
401
275
419
259
Receivables
0
7.6
38
Inventory
0
0.37
32.8
Other current assets
3.03
3.36
2.33
2.56
5.68
1.45
1.92
0
8.54
13.5
Total current assets
109
133
83.3
62.3
299
448
490
581
603
528
Property, plant and equipment
0.26
0.27
0.37
0.28
0.19
0.28
0.02
0.01
0
0.18
Lease right-of-use assets
0.72
0.29
0.98
1.04
1.49
2.02
1.34
Long-term investments
3.25
0
5.47
29.8
120
0
Other non-current assets
0.24
0.23
0.22
0.2
1.27
0
0.81
0.46
0
Total assets
109
137
83.9
63.5
301
450
497
613
725
530
Accounts payable
2.38
2.23
1.44
6.18
3.51
5.67
4.35
9.96
11.6
16.6
Accrued liabilities
1.64
2.39
2.8
2.8
3.21
4.34
5.95
11.2
14.5
24.4
Deferred revenue
1.22
1.57
1.52
1.52
1.52
Short-term debt
0
344
344
Total current liabilities
10.4
15.8
16.1
18.4
18.9
20.7
29.1
58.1
104
120
Long-term debt
0
332
Lease liabilities
0.42
0.1
0.71
0.71
0.58
1.58
Other non-current liabilities
0.29
0.31
0.14
0.01
0
Total liabilities
24.9
32.9
30.9
31.9
48.4
41.3
29.8
58.7
437
465
Total debt
0
338
350
Paid-in capital
389
471
492
527
821
952
1,161
1,456
1,509
1,571
Retained earnings
-305
-366
-439
-495
-569
-544
-693
-902
-1,221
-1,507
Shareholders' equity
84.1
104
53
31.6
252
408
467
554
288
64.6
Total equity
84.1
104
53
31.6
252
408
467
554
288
64.6
Total liabilities and equity
109
137
83.9
63.5
301
450
497
613
725
530
Shares outstanding
18.2
24.4
24.8
27.1
47.9
55
68.1
84.8
85.7
87.4
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-44.5
-60.8
-74
-56
-73.2
24.9
-149
-209
-319
-285
Depreciation and amortization
0.09
0.08
0.08
0.09
0.09
43
33
12
8
6
Stock-based compensation
4.71
5.45
6.2
6.01
9.06
13.3
16
31
43
47.5
Change in receivables
0
0
-7.6
-30.4
Change in inventory
0
0
-0.37
-32.1
Change in payables
0.92
-0.19
-0.79
4.74
-2.67
2.16
-1.32
5.61
1.67
4.95
Cash from operations
-35.2
-47.4
-68.5
-50.6
-71.3
29.1
-134
-161
-275
-323
Capital expenditures
-0.26
-0.08
-0.19
0
-0.13
0
0
0
-0.19
Purchases of investments
-158
-152
-78.8
-104
-279
-295
-495
-355
-557
-196
Cash from investing
-18.3
-17.1
51.4
12.8
-143
-40.9
-186
118
-220
290
Stock issued
2.06
0.28
0.03
0.18
6.63
6.34
11.5
5.13
8
12.1
Cash from financing
54.2
75.7
15.7
28.6
304
118
172
264
353
13.7
Net change in cash
0.76
11.3
-1.4
-9.26
90.6
107
-148
221
-141
-19.3
Free cash flow
-35.4
-47.5
-68.7
-71.3
29
-134
-161
-275
-323
Interest paid
0
1.63
2
2.06
0
0
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $18.20 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-77.1%
Operating income / revenue.
Net margin
-87.6%
Net income / revenue.
Operating cash flow margin
-87.6%
Cash from operations / revenue.
Return on equity (ROE)
-1,462.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-31.4%
Net income / average total assets.
Return on invested capital (ROIC)
-535.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
103.9%
Research and development expense / revenue.
Stock-based pay / revenue
19.6%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
627.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 5y
157.7%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-77.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-48.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-23.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-26.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
2.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
12.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
12.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
16.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.77x
Current assets / current liabilities.
Quick ratio
5.50x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.50x
(Cash + short-term investments) / current liabilities.
Debt / equity
23.2x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
49.7%
Total debt / total assets.
Liabilities / assets
97.9%
Total liabilities / total assets.
Net debt
-$197.9M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.83
Revenue / diluted weighted shares.
Operating cash flow per share
-$2.48
Cash from operations / diluted weighted shares.
Book value per share
$0.17
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
6.45x
Market cap / revenue.
P/B
108x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
108x
Market cap / tangible book value, when positive.
EV/Sales
5.66x
Enterprise value / revenue.
Earnings yield
-13.6%
Net income / market cap (the inverse of P/E).
What was Syndax Pharmaceuticals Inc's revenue in fiscal 2025?
Syndax Pharmaceuticals Inc reported revenue of $172.4M for fiscal 2025, 627.8% higher than the year before.
Was Syndax Pharmaceuticals Inc profitable in fiscal 2025?
No. It reported a net loss of $285.4M.
How much free cash flow did Syndax Pharmaceuticals Inc generate in fiscal 2025?
Cash from operations of $323.0M minus capital expenditures of $187.0K left free cash flow of -$323.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.